Correction to:“Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up”
D Planchard, S Popat, K Kerr, S Novello… - Annals of …, 2019 - annalsofoncology.org
1. In KEYNOTE-189, patients with metastatic non-squamous NSCLC, PS 0-1, without
sensitising EGFR or ALK mutations, were randomised to receive pemetrexed and a platinum …
sensitising EGFR or ALK mutations, were randomised to receive pemetrexed and a platinum …
[HTML][HTML] Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer
L Gandhi, D Rodríguez-Abreu, S Gadgeel… - New England journal …, 2018 - Mass Medical Soc
Background First-line therapy for advanced non–small-cell lung cancer (NSCLC) that lacks
targetable mutations is platinum-based chemotherapy. Among patients with a tumor …
targetable mutations is platinum-based chemotherapy. Among patients with a tumor …
Pembrolizumab plus pemetrexed‐platinum for metastatic nonsquamous non–small‐cell lung cancer: KEYNOTE‐189 Japan Study
H Horinouchi, N Nogami, H Saka, M Nishio… - Cancer …, 2021 - Wiley Online Library
Pembrolizumab plus pemetrexed‐platinum significantly improved overall survival (OS) and
progression‐free survival (PFS) with manageable safety compared with placebo plus …
progression‐free survival (PFS) with manageable safety compared with placebo plus …
Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label …
CJ Langer, SM Gadgeel, H Borghaei… - The lancet …, 2016 - thelancet.com
Background Limited evidence exists to show that adding a third agent to platinum-doublet
chemotherapy improves efficacy in the first-line advanced non-small-cell lung cancer …
chemotherapy improves efficacy in the first-line advanced non-small-cell lung cancer …
FP13. 02 pembrolizumab+ pemetrexed-platinum vs pemetrexed-platinum for metastatic NSCLC: 4-year follow-up from KEYNOTE-189
J Gray, D Rodríguez-Abreu, SF Powell… - Journal of Thoracic …, 2021 - jto.org
Methods Patients were randomized (2: 1) to intravenous pembrolizumab 200 mg or placebo
Q3W for up to 35 cycles (2 years). All patients received pemetrexed and investigator's choice …
Q3W for up to 35 cycles (2 years). All patients received pemetrexed and investigator's choice …
[HTML][HTML] Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final …
D Rodríguez-Abreu, SF Powell, MJ Hochmair… - Annals of …, 2021 - Elsevier
Background In the phase III KEYNOTE-189 study (NCT02578680), pembrolizumab plus
pemetrexed and platinum-based chemotherapy (pemetrexed–platinum) significantly …
pemetrexed and platinum-based chemotherapy (pemetrexed–platinum) significantly …
Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non …
MC Garassino, S Gadgeel, E Esteban, E Felip… - The Lancet …, 2020 - thelancet.com
Background Pembrolizumab plus pemetrexed–platinum led to superior overall survival and
progression-free survival, and a higher proportion of patients with a confirmed complete or …
progression-free survival, and a higher proportion of patients with a confirmed complete or …
Updated analysis from KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non–small-cell …
S Gadgeel, D Rodríguez-Abreu, G Speranza… - Journal of clinical …, 2020 - ascopubs.org
PURPOSE In KEYNOTE-189, first-line pembrolizumab plus pemetrexed-platinum
significantly improved overall survival (OS) and progression-free survival (PFS) compared …
significantly improved overall survival (OS) and progression-free survival (PFS) compared …
OA05. 07 IMpower132: PFS and safety results with 1L atezolizumab+ carboplatin/cisplatin+ pemetrexed in stage IV non-squamous NSCLC
V Papadimitrakopoulou, M Cobo, R Bordoni… - Journal of Thoracic …, 2018 - jto.org
Background In addition to the combination of atezolizumab (anti–PD-L1)+ platinum+
taxane±bevacizumab, non-squamous NSCLC patients may derive benefit from adding …
taxane±bevacizumab, non-squamous NSCLC patients may derive benefit from adding …
[HTML][HTML] 24-month overall survival from KEYNOTE-021 cohort G: Pemetrexed and carboplatin with or without Pembrolizumab as first-line therapy for advanced …
H Borghaei, CJ Langer, S Gadgeel… - Journal of Thoracic …, 2019 - Elsevier
Abstract Introduction Cohort G of KEYNOTE-021 (NCT02039674) evaluated the efficacy and
safety of pembrolizumab plus pemetrexed-carboplatin (PC) versus PC alone as first-line …
safety of pembrolizumab plus pemetrexed-carboplatin (PC) versus PC alone as first-line …